Citations

Clear

350 citation(s) found for "Stevens, V".

Localized vagina/uterus rhabdomyosarcoma (VU RMS): Results of a pooled analysis from four international cooperative groups.
Anderson, James Robert, Schwob, Dominique, Rodeberg, David A. , Martelli, Hélène , Walterhouse, David , Arndt, Carola A.S., Rey, Annie, Oberlin, Odile, Meder, Christine, Minard‐Colin, Véronique , Anderson, James Robert, Bisogno, Gianni , Stevens, Michaël C.G. , Ferrari, Andrea , Salvo, Gian Luca De , Hawkins, Douglas S.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 10063-10063

10.1200/jco.2015.33.15_suppl.10063 Get It

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease
Novak, Gregor , Stevens, Toer , Viegen, Tanja van, Bossuyt, Peter , Štabuc, Borut, Jeyarajah, Jenny , Zou, Guangyong , Gaemers, Ingrid C., McKee, Trevor D. , Fu, Fred , Shackelton, Lisa M. , Khanna, Reena , Sandborn, William J. , Feagan, Brian G. , Pai, Rish K. , D’Haens, Geert , Sandborn, W J , Feagan, B G , Vande Casteele, N , BRINK, Gijs R. VAN DEN , Jairath, Vipul , Casteele, Niels Vande , Zou, Guangyong , Bossuyt, Peter

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 15, 2019 | Volume: 49 | Issue: 11 | Pages: 1401-1409

10.1111/apt.15250 | PMID 30983024 Get It

SummaryBackgroundThe appropriate location for biopsy procurement relative to an ulcer in active Crohn's disease is unknown.AimTo explore the relationship between biopsy location, histological disease activity, proinflammatory gene expression and the presence of inflammatory cells.MethodsFifty‐one patients with Crohn's disease and ulcers >0.5 cm diameter in the colon and/or ileum were prospectively enrolled at three centres. Biopsies were obtained from 0 mm, 7 to 8 mm and 21 to 24 mm from the edge of the largest ulcer. Histological activity was blindly assessed with the Global Histological Disease Activity Score, the Robarts Histopathology and Nancy Histological indices. Messenger ribonucleic acid (mRNA) levels for interleukins‐6, ‐8 and ‐23 (p19 and p40 subunits), CD31 and S100A9 were measured using quantitative polymerase chain reaction. The number of CD3+, CD68+ and myeloperoxidase‐positive cells was quantified by immunohistochemistry. Data were analysed using mixed models with location and segment as fixed effects and patients as random effect to account for correlation among segments within a patient.ResultsHistological disease activity scores (P < 0.0001), proinflammatory gene expression levels (P < 0.005) and numbers of myeloperoxidase‐positive cells (P < 0.0001) were highest in biopsies from the ulcer edge in the colon and ileum, with decreasing gradients observed with distance from the edge (P < 0.05). No differences between colonic and ileal samples were detected for the parameters measured at any location.ConclusionsBiopsies from the ulcer edge in patients with Crohn's disease yielded the greatest histological disease activity and mRNA levels and had similar readouts in the colon and ileum. Research is needed to confirm this conclusion for other measures.
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines
Chang, Susan M. , Messersmith, Hans , Ahluwalia, Manmeet S. , Gaspar, Laurie E., Gatson, Na Tosha , Khasraw, Mustafa , Lassman, Andrew B. , Maués, Julia , Mrugała, Maciej M. , Raizer, Jeffrey J. , Schiff, David , Stevens, Glen , Sumrall, Ashley , Bent, Martin J. van den , Vogelbaum, Michael A. , van den Bent, Martin J , Khasraw, Mustafa , Gatson, Na Tosha N , Messersmith, Hans , Sumrall, Ashley , Ahluwalia, Manmeet S , Chang, Susan Marina , Andrews, David William , Brastianos, Priscilla K. , Jordan, Justin T.

Mayo Clinic

Journal of Clinical Oncology | March 18, 2019 | Volume: 37 | Issue: 13 | Pages: 1130-1135

10.1200/jco.18.02085 | PMID 30883246 Get It

PURPOSE The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The Expert Panel voted to endorse the two guidelines, and ASCO and Society for Neuro-Oncology (SNO) independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based on the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines with minor alterations. RECOMMENDATIONS Key recommendations include the following: prophylactic antiepileptic drugs were not recommended for routine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases. Additional information is available at www.asco.org/neurooncology-guidelines .
Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones
Dierselhuis, Edwin F. , Goulding, Krista , Stevens, Martin , Jutte, Paul C. , Jutte, Paul

Mayo Clinic

Cochrane Database of Systematic Reviews | March 7, 2019 | Volume: 2019 | Issue: 4 | Pages: No page available

10.1002/14651858.cd010778.pub2 | PMID 30845364 Get It

Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes
Mendes‐Soares, Helena , Raveh-Sadka, Tali, Azulay, Shahar, Edens, Kim, Ben‐Shlomo, Yatir , Ofek, Tal, Bachrach, Davidi, Stevens, Josh , Segal, Lihi, Kashyap, Purna , Nelson, Heidi , Colibaseanu, Dorin , Cohen, Yossi

Mayo Clinic

JAMA Network Open | February 8, 2019 | Volume: 2 | Issue: 2 | Pages: e188102

10.1001/jamanetworkopen.2018.8102 | PMID 30735238 Get It

The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Kleckner, Ian R. , Barton, Debra L. , Mustian, Karen M. , O’Mara, Ann M., Germain, Diane St. , Cavaletti, Guido , Danhauer, Suzanne C. , Hopkins, Judith O. , Kelly, Katherine Patterson , Loprinzi, Charles L. , McLeod, Howard L. , Mohile, Supriya G. , Rowland, Julia H. , Salvemini, Daniela, Segal, Rosalind A. , Stevens, Worta McCaskill, Janelsins, Michelle C. , Dorsey, Susan G. , Hershman, Dawn L. , Hohmann, Andrea G. , Höke, Ahmet , Paice, Judith A. , Lavoie Smith, Ellen M , McCaskill‐Stevens, Worta

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 26, 2019 | Volume: 111 | Issue: 6 | Pages: 531-537

10.1093/jnci/djz011 | PMID 30715378 Get It

Abstract Although recent scientific advances have improved our understanding of basic biological mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN), few interventions are available to prevent or treat CIPN. Although some biological targets from preclinical studies show promise in nonhuman animal models, few targets have been translated to successful clinical trials. To address this problem, the National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Committee convened a meeting of experts in the CIPN and oncology symptom management fields to participate in a Clinical Trials Planning Meeting (CTPM). Investigators presented data from preclinical and translational studies for possible CIPN interventions; these were evaluated for readiness of randomized clinical trial testing by experts, and recommendations were provided. Breakout sessions were convened to discuss and develop future studies. The CTPM experts concluded that there is compelling evidence to move forward with selected pharmacological and nonpharmacological clinical trials for the prevention and treatment of CIPN. Several key feasibility issues need to be addressed, however. These include identification of optimal outcome measures to define the CIPN phenotype, establishment of parameters that guide the evaluation of clinically meaningful effects, and adoption of approaches for inclusion of translational and biomarker and/or genetic measures. The results of the CTPM provide support for conducting clinical trials that include both pharmacological and nonpharmacological approaches, alone or in combination, with biomarkers, genetics, or other measures designed to inform underlying CIPN mechanisms. Several working groups were formed to design rigorous CIPN clinical trials, the results of which are ongoing.
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, Melanie D. , Montagne, Axel , Nation, Daniel A. , Schneider, Lon S. , Chui, Helena C., Harrington, Michael G. , Pa, Judy , Law, Meng , Wang, Danny J.J. , Jacobs, Russell E. , Doubal, Fergus , Ramirez, Joel , Dichgans, Martin , Love, Seth , Bath, Philip M. , Markus, Hugh S. , Salman, Rustam Al‐Shahi , Kalaria, Rajesh N., Werring, David J. , Moskowitz, Michael A., Katušić, Zvonimir S. , Lazarov, Orly , Rehman, Jalees , Wellington, Cheryl L. , González, Héctor M. , Yuan, Chun , Lockhart, Samuel N. , Hughes, Timothy M. , Chen, Christopher , Sachdev, Perminder S. , O’Brien, John T. , Pantoni, Leonardo , Gustafson, Deborah , Biessels, Geert Jan , Wallin, Anders , Wong, Adrian , Passmore, Peter , Barkof, Frederick, Muller, Majon , Román, Gustavo C. , Hamel, Édith , Seshadri, Sudha , Buchem, Mark A. van , Arvanitakis, Zoe , Drewes, Lester R. , Hachinski, Vladimir , Wardlaw, Joanna M. , Kalaria, Raj N. , Dichgans, Martin , O'Brien, John Tiernan , Wardlaw, Joanna Marguerite , Seshadri, Sudha , Sachdev, Perminder S , Sagare, Abhay P. , Chui, Helena C. , Black, Sandra E. , Nedergaard, Maiken , Benveniste, Helene , Iadecola, Costantino , Allan, Stuart McRae , Quinn, Terence J , Carare, Roxana Octavia , Touyz, Rhian M. , Williams, Steven , Lutz, Sarah E. , Minshall, Richard D. , Davis, Thomas P. , Gonzalez, Hector M , Skoog, Ingmar , Biessels, Geert Jan , Smith, Eric Edward , Mok, Vincent , Breteler, Monique M.B. , Gottesman, Rebecca F. , Schneider, Julie A. , Finch, Caleb E. , Toga, Arthur W. , Zloković, Berislav V. , Al-Shahi Salman, Rustam , Werring, David John , Wang, Danny J J

Mayo Clinic

Alzheimer's & Dementia | January 11, 2019 | Volume: 15 | Issue: 1 | Pages: 158-167

10.1016/j.jalz.2018.07.222 | PMID 30642436 Get It

Abstract Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging–Alzheimer's Association describes a biomarker‐based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood‐brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
Diab, Osama , McEntire, Dan, Kassim, Thamer , Nayfeh, Ali , Dajani, Abdel, Kerfeld, Mitchell J. , Campbell, Jonathon, Alsuwaidan, Adbullah, Hazeem, Mahmoud Abu , Gbadamosi-Akindele, Maryam

Mayo Clinic

Case Reports in Oncological Medicine | January 8, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-4

10.1155/2019/7928752 | PMID 30729055 Get It

Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to be aware of this relationship.